logo-loader
viewTilray Inc

Tilray raises $435 million via convertible debt offering

A portion of the money raised will go to paying off the $9.1 million existing mortgage on its facility in British Columbia

Marijuana leaves
The Canadian company distributes medical cannabis in 12 countries

Tilray Inc (NASDAQ:TLRY) shares dipped following the close of its convertible debt offering.

The cannabis company announced last week that it would offer $450 million worth of convertible senior notes due in 2023 in a private placement to qualified institutional buyers.

READ: Tilray acquires Alef Biotechnology to expand cannabis presence in Latin America

After expenses, the company raised a total of $435 million. The initial offer was worth $400 million, but was later upsized.

The 5.00% notes will be convertible into cash, shares of its Class 2 common stock, or a combination of the two.

The proceeds will go towards working capital, acquisitions and corporate expenses as well as paying off the $9.1 million existing mortgage on its facility in British Columbia.

The Canadian cannabis company cultivates and distributes medical cannabis to 12 countries, including Canada, Australia, New Zealand and Germany.

Shares of Tilray were down more than 4% to $130.94 in Thursday pre-market trading.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

 

Quick facts: Tilray Inc

Price: 19.24 USD

NASDAQ:TLRY
Market: NASDAQ
Market Cap: $1.92 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

4 hours, 12 minutes ago

2 min read